Johnson & Johnson (NYSE:JNJ) Issues Earnings Results

Key Points

• Q1 beat and raised guidance: Johnson & Johnson reported EPS of $2.70 (vs. $2.68 est.) and revenue of $24.06 billion (vs. $23.60B est.), and updated FY‑2026 guidance to $11.450–$11.650 EPS.
• Dividend hike: The board raised the quarterly dividend 3.1% to $1.34, marking the 64th consecutive annual increase.
• Stelara pressure offset by other brands: Stelara sales plunged after loss of patent protection, a material headwind, but management said stronger demand for drugs like Darzalex and Tremfya helped offset the impact this quarter.

Johnson & Johnson (NYSE:JNJ - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.02, FiscalAI reports. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The company had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson updated its FY 2026 guidance to 11.450-11.650 EPS.

Johnson & Johnson Trading Down 0.2%

Shares of Johnson & Johnson stock opened at $238.00 on Tuesday. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The firm has a market cap of $573.25 billion, a price-to-earnings ratio of 21.54, a price-to-earnings-growth ratio of 2.38 and a beta of 0.34. The business has a fifty day simple moving average of $241.44 and a 200-day simple moving average of $215.95. Johnson & Johnson has a fifty-two week low of $146.12 and a fifty-two week high of $251.71.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q1 earnings beat estimates and management raised the full‑year outlook; company cited strong demand for Darzalex and Tremfya and multiple recent approvals, signaling momentum across the portfolio. J&J's first-quarter profit beats estimates even as Stelara sales disappoint
• Positive Sentiment: Company-released Q1 results and management commentary emphasize accelerated growth initiatives and pipeline strength, reinforcing the upbeat guidance. Johnson & Johnson reports Q1 2026 results, raises 2026 outlook
• Positive Sentiment: Board raised the quarterly dividend 3.1% to $1.34 (annualized $5.36), marking the 64th consecutive annual increase — supports appeal to income and dividend‑growth investors. Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%
• Positive Sentiment: At least one shop raised JNJ’s price target to $267, reflecting analyst confidence after the quarter. Johnson & Johnson NYSE: JNJ Price Target Raised to $267.00
• Neutral Sentiment: Pre-earnings analyst previews and market commentary positioned JNJ as a stable, large‑cap healthcare name vs. higher‑growth peers; broader market rallies also provide context for stock moves. Ahead-of-Q1 earnings: what do analysts think about JNJ?
• Negative Sentiment: Stelara sales plunged sharply (loss of patent protection cited), which is a material revenue headwind; management says other brands offset the hit this quarter, but continued Stelara erosion could pressure longer‑term growth if not fully replaced. J&J's first-quarter profit beats estimates even as Stelara sales disappoint

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 1,322 shares of the company's stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at $6,251,310.02. This represents a 4.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the company's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares of the company's stock, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 30,142 shares of company stock valued at $7,360,528. Insiders own 0.16% of the company's stock.

Institutional Investors Weigh In On Johnson & Johnson

A number of institutional investors and hedge funds have recently modified their holdings of JNJ. Price T Rowe Associates Inc. MD raised its position in shares of Johnson & Johnson by 41.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,423,886 shares of the company's stock worth $2,571,124,000 after purchasing an additional 3,655,754 shares during the period. Amundi raised its position in shares of Johnson & Johnson by 19.3% during the third quarter. Amundi now owns 13,354,936 shares of the company's stock worth $2,512,719,000 after purchasing an additional 2,163,838 shares during the period. Marshall Wace LLP raised its position in shares of Johnson & Johnson by 126.3% during the third quarter. Marshall Wace LLP now owns 3,584,162 shares of the company's stock worth $664,575,000 after purchasing an additional 2,000,609 shares during the period. GQG Partners LLC raised its position in shares of Johnson & Johnson by 28.4% during the fourth quarter. GQG Partners LLC now owns 7,752,266 shares of the company's stock worth $1,604,336,000 after purchasing an additional 1,714,687 shares during the period. Finally, State Street Corp raised its position in shares of Johnson & Johnson by 1.3% during the fourth quarter. State Street Corp now owns 133,869,843 shares of the company's stock worth $27,704,364,000 after purchasing an additional 1,663,782 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Scotiabank reiterated an "outperform" rating on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Wolfe Research boosted their price target on Johnson & Johnson from $225.00 to $240.00 and gave the stock an "outperform" rating in a research report on Monday, January 5th. Bank of America reiterated a "neutral" rating on shares of Johnson & Johnson in a research report on Monday, March 2nd. Daiwa Securities Group boosted their price target on Johnson & Johnson from $203.00 to $237.00 and gave the stock an "outperform" rating in a research report on Thursday, January 29th. Finally, Freedom Capital lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Friday, January 16th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus price target of $238.17.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.